Atrium Therapeutics
Open
$12.31
Prev. Close
$12.29
High
$12.37
Low
$12.28
Market Snapshot
$191.92M
-3.0
47
Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. The company is headquartered in San Diego, California and currently employs 47 full-time employees. The company went IPO on 2026-02-27. Its technology leverages the targeted RNA delivery platform, which combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with oligonucleotides. The company is designed to allow selective targeting of the underlying genetic drivers of disease. Its development pipeline consists of programs that target genetically validated drivers of cardiomyopathy, which include Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2 (PRKAG2) and Phospholamban (PLN). Its genetic drivers are associated with PRKAG2 syndrome and PLN cardiomyopathy, which is a genetic heart condition associated with life-threatening forms of heart disease. Its programs are supported by preclinical data, in addition to positive clinical data generated in neuromuscular indications using the same RNA delivery platform technology.
Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. The company is headquartered in San Diego, California and currently employs 47 full-time employees. The company went IPO on 2026-02-27. Its technology leverages the targeted RNA delivery platform, which combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with oligonucleotides. The company is designed to allow selective targeting of the underlying genetic drivers of disease. Its development pipeline consists of programs that target genetically validated drivers of cardiomyopathy, which include Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2 (PRKAG2) and Phospholamban (PLN). Its genetic drivers are associated with PRKAG2 syndrome and PLN cardiomyopathy, which is a genetic heart condition associated with life-threatening forms of heart disease. Its programs are supported by preclinical data, in addition to positive clinical data generated in neuromuscular indications using the same RNA delivery platform technology.
Recently from Cashu
Avidity Biosciences Adjusts Stockholder Meeting for Novartis Merger and Distribution Timeline
Avidity Biosciences Gears Up for Strategic Merger and Stock Distribution Avidity Biosciences, Inc. announces a pivotal update regarding its special meeting of stockholders, originally set for February…
Avidity Biosciences Pursues Merger with Novartis and Atrium Stock Distribution Plan
Avidity Biosciences Advances Towards Major Merger and Stock Distribution Avidity Biosciences, Inc. confirms its commitment to enhancing shareholder value through a strategic merger with Novartis AG an…
Lilac and Soin seek RNA biomarkers for spinal cord stimulation; Avidity Biosciences (RNA) cited
Objective molecular readouts for spinal cord stimulation take shape PROVIDENCE/ DAYTON — Lilac Biosciences and Soin Neuroscience are launching a preclinical collaboration to test whether RNA expressio…
Lilac–Soin pursue RNA biomarkers to objectify spinal cord stimulation pain; implications for Avidity Biosciences
RNA readouts aim to objectify pain response Lilac Biosciences is partnering with Soin Neuroscience to test whether changes in RNA expression can serve as reproducible molecular signatures of response…